Maa: Yhdistynyt kuningaskunta
Kieli: englanti
Lähde: VMD (Veterinary Medicines Directorate)
Oxytetracycline
Zoetis UK Limited
QJ01AA06
Oxytetracycline
Solution for injection
POM-V - Prescription Only Medicine – Veterinarian
Cattle, Pigs, Sheep
Antimicrobial
Authorized
1990-07-27
Revised: November 2022 AN: 00972/2022 Page 1 of 6 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT TERRAMYCIN/LA 200 mg/ml Solution for Injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: ACTIVE SUBSTANCE: Oxytetracycline (as dihydrate) …………………200 mg EXCIPIENT: Sodium Formaldehyde Sulfoxylate…………….2.20 mg For the full list of excipients, see Section 6.1 3. PHARMACEUTICAL FORM Solution for injection. Light to dark yellowish brown solution. It may have a green tint. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Cattle, sheep and pigs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Cattle: for the treatment and control of pasteurellosis and pneumonia caused by oxytetracycline-sensitive organisms, and as an aid in the treatment of infectious bovine keratoconjunctivitis due to sensitive strains of _Moraxella bovis_. May also be of value for foul-in-the-foot. Pigs: for the treatment of pneumonia caused by _Pasteurella_. Sheep: for the control of enzootic abortion and pneumonia caused by oxytetracycline-sensitive organisms. The product may be an aid in the treatment of foot rot, acute severe mastitis, infectious ovine keratonconjunctivitis (pink- eye). 4.3 CONTRAINDICATIONS Not recommended for dogs, cats and horses. Revised: November 2022 AN: 00972/2022 Page 2 of 6 Use with caution in animals with hepatic or renal impairment. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Not to be injected subcutaneously. Bacterial resistance may exist or develop after prolonged use of tetracyclines. 4.5 SPECIAL PRECAUTIONS FOR USE i) Special precautions for use in animals It is recommended in cattle that not more than 10ml, and in sheep and pigs not more than 5 ml, be injected at any one intramuscular site (see also 4.9). Do not dilute. The period of time between first and last dose withdrawal from a multi- dose vial should not be longer than 28 days. Discard unused material. Contamination of broached vials during use should be avoided. If concurrent treatmen Lue koko asiakirja